- Charles River Laboratories (NYSE:CRL) initiated with Buy rating and $120 (14% upside) price target by Argus Research.
- Catalent (NYSE:CTLT) initiated with Outperform rating and $46 (15% upside) price target by RBC Capital Markets.
- MEDNAX (NYSE:MD) initiated with Overweight rating and $58 (12% upside) price target by Piper Jaffray.
- Envision Healthcare (NYSE:EVHC) initiated with Neutral rating and $35 (5% upside) price target by Piper Jaffray.
- Intercept Pharmaceuticals (NASDAQ:ICPT) and Vertex Pharmaceuticals (NASDAQ:VRTX) initiated with Strong Buy ratings by Deutsche Bank.
- Audentes Therapeutics (NASDAQ:BOLD) resumed with Overweight rating and $36 (31% upside) price target by Piper Jaffray.
- DENTSPLY SIRONA (NASDAQ:XRAY) upgraded to Overweight by JPMorgan.
- Bluebird bio (NASDAQ:BLUE) downgraded to Hold with a $200 (5% upside) price target by Maxim Group.
- Accelerate Diagnostics (NASDAQ:AXDX) downgraded to Neutral by BTIG Research.
- Genomic Health (NASDAQ:GHDX) downgraded to Underweight with a $25 (17% downside risk) by JPMorgan citing soft U.S. invasive breast cancer market and slower-than-expected reimbursement rate.
- Accuray (NASDAQ:ARAY) downgraded to Underweight by JPMorgan citing lack of consistency in quarterly earnings, competitive pressures and execution issues. $8 price target removed. Shares down 6% premarket on light volume.
Premarket analyst action - healthcare
Recommended For You
About CRL Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
CRL | - | - |
Charles River Laboratories International, Inc. |